Yuna Blum

I am a research scientist at the CIT Program (Cartes d’Identité des Tumeurs) at the French League Against Cancer.

Keywords: Genomics, biostatistics, bioinformatics

Our project COMETH is dedicated to big data integration in Health. We are currently developing a benchmarking platform dedicated to deconvolution methods for tumor heterogeneity quantification. Want to know more?

Deconbench: our first benchmarking platform

European coordinators:

Thanks again to all the participants for the great week and the intensive collaborative work! Hope to see everyone for a next edition of the challenge #hadaca2019 @programmeCIT @laliguecancer @TIMC_Lab @grenobledata @EIThealth_FR

Honored to receive this prize!  I presented our recent results on Cancer heterogeneity quantification using a deconvolution approach and its clinical impacts.  Thank you #ESMO19 and thank you to all my collaborators!

We are organizing together with the BMC TIMC-IMAG team – CNRS, the 2nd edition of an international health data challenge on statistical methods to quantify the cell populations in a tumor using omics data, one of the main current challenges in cancer genomics! Join us for this very exciting event ! More info https://tinyurl.com/hadaca2019

Honored to be part of this international consensus on #PancreaticCancer thank you so much to Paco Real and to #MSKCC people !

We won the first prize ! Thank you to the organizers for this amazing week, such great interactions and a wonderful location !

I presented a collaborative work with Didier Jean’s team (Functional genomics of solid tumor, Inserm Unit U1162, Hôpital Saint-Louis, Paris) about MPM heterogeneity characterization using molecular gradients. In our study, we show using a deconvolution approach, that molecular gradients bring new light on intra-tumor heterogeneity of MPM, leading to a reconsideration of existant MPM molecular classifications. We further show that this new way of thinking the pathology provides a significant contribution to clinical applications with implications in prognosis and therapeutic strategies, including immunotherapies and targeted therapies.

Scientific Paper: http://www.cell.com/cell-reports/abstract/S2211-1247(17)31606-6

In brief (french):